New cocktail aims to boost chemo power against aggressive lymphoma
NCT ID NCT04978584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a mix of targeted drugs (rituximab, lenalidomide, acalabrutinib, tafasitamab) before and with standard chemotherapy can better control a fast-growing type of lymphoma called DLBCL. About 62 adults with newly diagnosed disease will participate. The goal is to see if this approach improves tumor shrinkage and complete response rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?